Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Trial Evaluating Efficacy and Safety of Nivolumab (Optivo®) in Patients With COVID-19 Infection, Nested in the Corimmuno-19 Cohort. (CORIMUNO-NIVO)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04343144
Recruitment Status : Not yet recruiting
First Posted : April 13, 2020
Last Update Posted : April 14, 2020
Information provided by (Responsible Party):
Assistance Publique - Hôpitaux de Paris

No Study Results Posted on for this Study
Recruitment Status : Not yet recruiting
Estimated Primary Completion Date : July 31, 2020
Estimated Study Completion Date : September 30, 2020